Project leader

Dr. Fritz Andreae Phone:+43 316 681711 11 Fax:+43 316 681711 4 Email

Dr. Andreas Artl Phone:+43 316 681711 11 Fax:+43 316 681711 4 Email

 

Dr. Richard Froehlich Phone:+43 316 681711 17 Fax:+43 316 681711 4 Email

 

Ing. Thorsten Radolf Phone:+43 316 681711 18 Fax:+43 316 681711 4 Email

Institute presentation

piCHEM has more than 20 years of experience in the field of peptide chemistry for different applications. piCHEM is one of the experienced in this field in Europe and the team members are extensive skilled in this special area.  piCHEM therefore has been involved in the past in several EC projects  for severe lung therapy, in the field of synthetic vaccines at different stages of development (preclinical to Phase I and II trials) for Alzheimer Disease, Oncology, Atherosclerosis or HIV.
piCHEM itself was heading a national project for tPDT based on SSTR targeting peptides and modified haematoporphyrines  acting as photosensitizers (P81096). Besides piCHEM was also the producer of named Exendine-4 derivatives that were used for PPRT in the EC project BetaImage.
So the manufacturing and testing protocols and expertise for this special kind of peptides and labelling techniques for PDT are already developed and established successfully.


piCHEM will serve as the peptide supplier and partner for supporting all kinds of chemical modifications and analytical task to its partners in WP2  to develop new and novell GLP-1R targeting compounds.
In WP3  piCHEM will be responsible for the GMP production, release and stability testing of mentioned GMP tracers for IGS and tPDT. Also for generating the CMC section of the submission dossiers. piCHEM through its Qualified Person, will also take care of the technical release of the products for use in the clinical trials. It will also be strongly involved in exploitation of this project as the foreseen commercial manufacturing site.